Sotera Health Intrinsic Value – Sotera Health Reaches New Low of $108.50 in 2023.
March 28, 2023
Trending News 🌧️
The stock market has been volatile throughout the year, and Sotera Health ($NASDAQ:SHC) has been no exception. On Wednesday, the healthcare company’s stock price hit a new 52-week low of $108.50. Sotera Health’s stock has been on a downward trajectory in recent months due to a variety of factors. These include changes in healthcare policy, a decrease in demand for their services and products due to the pandemic, and a general lack of investor confidence. Despite the current downturn, Sotera Health remains a strong and well respected healthcare provider. The company has been making strides to improve their operational efficiency and reduce their costs in an effort to remain competitive in the healthcare industry.
They have also been making progress in expanding their product range to better meet the needs of their customers. Sotera Health also recently announced they were entering into a partnership with a major health insurance provider to increase access to quality care. While Sotera Health’s stock price has hit a new low, the company remains confident that they will recover and rebound in the future. The healthcare sector is still expected to be one of the biggest growth areas over the next decade, and Sotera Health is well-positioned to take advantage of this. With their commitment to providing quality care and innovative products, they are in a good position to capitalize on future opportunities.
Price History
Monday saw SOTERA HEALTH drop to a new low, closing at $108.50. This comes despite news coverage mostly being negative, with the stock opening at $17.5 and closing at the same price, up by 1.3% from prior closing price of 17.3. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Sotera Health. More…
| Total Revenues | Net Income | Net Margin |
| 1k | -233.57 | 16.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Sotera Health. More…
| Operations | Investing | Financing |
| 277.96 | -181.9 | 197.76 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Sotera Health. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 3.12k | 2.77k | 1.24 |
Key Ratios Snapshot
Some of the financial key ratios for Sotera Health are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 8.8% | 9.5% | -16.2% |
| FCF Margin | ROE | ROA |
| 9.5% | -21.3% | -3.3% |
Analysis – Sotera Health Intrinsic Value
At GoodWhale, we recently conducted an analysis of SOTERA HEALTH‘s wellbeing, and what we found was quite interesting indeed. Our proprietary Valuation Line helped us to determine the intrinsic value of SOTERA HEALTH’s shares, which we calculated to be around $22.3. Interestingly, the current market price of SOTERA HEALTH stock is currently at $17.5, meaning that it is currently undervalued by a whopping 21.5%. We believe that this presents an excellent opportunity for investors to buy into the company at a discounted price. More…
Peers
The company has a strong presence in the United States, Europe, and Asia. Pharmigene Inc, Inotiv Inc, and Centogene NV are all major competitors of Sotera Health Co.
– Pharmigene Inc ($TPEX:7595)
Pharmigene Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for the treatment of cancer and other diseases. The company’s lead product candidate is PG-301, a precision cancer medicine targeting the EZH2 protein. Pharmigene is also developing PG-201, a precision medicine targeting the KRAS protein, and PG-102, a precision medicine targeting the BRAF protein.
Pharmigene’s market cap is $658.49 million as of 2022. The company’s return on equity is -6.26%.
Pharmigene’s lead product candidate, PG-301, is a precision cancer medicine targeting the EZH2 protein. The company is also developing PG-201, a precision medicine targeting the KRAS protein, and PG-102, a precision medicine targeting the BRAF protein.
– Inotiv Inc ($NASDAQ:NOTV)
Inotiv Inc is a biotechnology company that focuses on the discovery and development of innovative therapies to treat patients with cancer and other serious diseases. The company’s market cap is $486.81M as of 2022, and its ROE is -6.96%. Inotiv’s products are designed to target the underlying cause of disease and improve patient outcomes. The company’s lead product candidates are in clinical trials for the treatment of solid tumors and blood cancers. Inotiv is headquartered in San Diego, California.
– Centogene NV ($NASDAQ:CNTG)
As of 2022, Centogene NV has a market cap of 28.16M. The company’s return on equity is -141.43%. Centogene NV is a biotechnology company that focuses on the diagnosis, treatment, and prevention of rare diseases. The company was founded in 2002 and is headquartered in Rostock, Germany.
Summary
Investors in Sotera Health have seen a significant decrease in share price over the past year, dropping to a new low of $108.50 in 2023. At the time of writing, news coverage of the company is mostly negative. Analysts suggest that investors should be wary of investing in Sotera Health due to the stock’s volatile nature and lack of an attractive growth story. The company’s operations remain unprofitable, and the macroeconomic situation has not yet improved enough to provide the necessary tailwinds for a turnaround.
Investors should also note that much of Sotera Health’s operations are tied to the pharmaceutical and biotechnology industries, which have been affected by the pandemic. As such, further downside risk should be expected if conditions do not improve.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
